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ABSTRACT  
Dapagliflozin (DG) is a sodium glucose cotransporter-2 (SGLT-2) inhibitor and 
Saxagliptin (SG) is a dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of the 
present work is to formulate a bilayered tablet (BT) of DG as immediate release 
(IR) layer and SG as sustained release (SR) layer by direct compression method for 
the effective treatment of type 2 diabetes mellitus. Type and concentration of 
superdisintegrant among [sodium starch glycolate (SSG)/Lycoat RS720/ Ludiflash] 
was optimized to enhance the dissolution rate (DR) of DG from the IR layer of BT. 
Type and concentration of SR polymer among (Carbapol 940/ Karaya gum/ HPMC 
K15M) was optimized to extend the release of SG up to 12 h with zero order 
release profile from the SR layer of BT. It was concluded that the optimization of 
the ratio of SG: SR polymer (HPMC K15M), had significant effect on extending the 
release profiles of SG. The ratio of SG: HPMC K15M at 1:18 respectively forms a 
better matrix for the extending the release of SG up to 12 h from the SR layer of BT. 
The optimized formulation; BT9 [IR9 (6% w/w Ludiflash as superdisintegrant and 
SR9 (with 60% HPMC K15M as SR polymer)] releases 100% of DG from the IR 
layer with in 45 min and extends the release of SG up to 12 h with a better zero 
order release profile (r2=0.994). It passes the accelerated stability studies as per 
ICH guidelines. A combination of these two classes [SGLT-2 inhibitors (DG) and 
DPP-4 inhibitors (SG)] of glucose-lowering agents and formulating them as a BT is 
more effective in the treatment and maintenance of type 2 diabetes mellitus. 
INTRODUCTION
The main objective of combination therapy is to 
encourage the utilization of lower doses of drugs to 
treat patients and also to minimize dose dependent 
side effect and adverse reactions.[1-2] Bilayered 
tablets can be a primary option to avoid chemical 
incompatibilities between different drugs by 
physical separation, and to enable the development 
of different drug release profiles [immediate release 
(IR) with extended release (ER)]. Applications of 
bilayered tablets are mainly used in the combination 
therapy; to deliver the loading dose and sustained 
dose of the same or different drugs and are used to 
deliver the two different drugs having different 
release profiles [3]. Type 2 diabetes mellitus is a 
progressive disease with multiple underlying patho-
physiologic defects. Monotherapy alone cannot 
maintain glycemic control and leads to treatment 
failure. Ideally, a combination of glucose-lowering 
agents should have complementary mechanisms of 
action that address multiple patho-physiologic 
pathways, can be used at all stages of the disease, 
and be generally well tolerated with no increased 
risk of hypoglycemia, cardiovascular events, or 
weight gain. Two classes of glucose-lowering agents 
that meet these criteria are Dapagliflozin (DG); a 
sodium glucose cotransporter-2 (SGLT-2) inhibitors 
and Saxagliptin (SG); a dipeptidyl peptidase-4 (DPP-
4) inhibitors. The aim of this present work is to 
formulate a bilayered tablet of Dapagliflozin (as IR 
layer) and Saxagliptin (as SR layer) by direct 
compression method using various extended release 
polymers such as HPMC K15M, Karaya gum and 
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Carbapol 940, for the effective treatment of type 2 
diabetes mellitus. 
MATERIALS AND METHODS 
Materials  
Dapagliflozin (DG) and Saxagliptin (SG) were 
obtained as gift samples from M/s Concord Drugs 
Ltd., Hyderabad, India. Sodium starch glycolate 
(SSG), Lycoat RS 720, Ludiflash, Carbapol 940, 
Karaya gum, HPMC K15M, PVP K30, 
Microcrystalline cellulose (MCC), Magnesium 
stearate and Talc were purchased from S.D. Fine-
Chem Ltd., Chennai, India. All the excipients used in 
study are of analytical grade. 
Drug-excipient compatibility studies by FT-IR  
FT-IR spectra of pure drug(s) and drug: polymer 
(1:1) physical mixtures were recorded out, in the 
region of 400-4000 cm-1 at spectral resolution of 2 
cm-1, by the potassium bromide pellet method using 
(Shimadzu-1800, Japan) [4]. The interpretation 
results of FT-IR spectra were shown in Fig. 1 and 
Table 1.  
Calibration curve of Dapagliflozin and 
Saxagliptin in 0.1N HCl and Saxagliptin in pH 6.8 
Phosphate buffer  
100 mg of pure drug was dissolved in 100 mL of 
0.1N HCl/ pH 6.8 Phosphate buffer (stock solution-
I; 1000 μg/mL) and then placed in an sonicator for 
10 min, from this 10 mL of solution was taken and 
the volume was adjusted to 100 mL with 0.1N HCl/ 
pH 6.8 Phosphate buffer (stock solution-II; 100 
μg/mL). The stock solution-II; was suitably diluted 
with 0.1N HCl/ pH 6.8 Phosphate buffer to obtain 
the series of working dilutions: 5, 10, 15, 20, 25 and 
30 μg/mL of drug solution. The median 
concentration was scanned for λmax and at the 
respective λmax working dilutions were analyzed by 
using a double beam UV-Vis spectrophotometer (PG 
instruments T60, UK). The standard calibration 
curve was plotted by taking concentration on X-axis 
and absorbance on Y-axis was shown in Fig. 2. 
Preparation of immediate release layer  
DG, superdisintegrants (SSG/Lycoat RS 720/ 
Ludiflash), PVPK30 and MCC were weighed and co-
sifted through sieve No. # 40 (ASTM), blended in a 
poly bag for 10 min and lubricated with sieve No. # 
60 (ASTM) passed magnesium stearate and talc by 
mixing in the same poly bag, for additional 2-3 min; 
which is used as upper IR layer [5]. 
Preparation of sustained release layer  
SG, SR polymer (Carbapol 940/ Karaya gum/ HPMC 
K15M), PVP K30 and MCC were weighed were co- 
sifted through sieve No. # 40 (ASTM), blended in a 
poly bag for 10 min and lubricated with sieve No. # 
60 (ASTM) passed magnesium stearate and talc by 
mixing in the same poly bag, for additional 2-3 min; 
which is used as lower SR layer. Composition of 
Dapagliflozin (IR) layer and Saxagliptin (SR) layer 
of bilayered tablets is given in Table 2. 
Pre-compression studies  
Directly compressible tablet blends of DG-IR layer 
and SG-SR layer were evaluated for [angle of repose 
(θ), bulk density (BD), tapped density (TD), Carr’s 
Index (CI) & Hausner’s Ratio (HR)]. Limits for 
powder flow characteristics as per USP are 
mentioned in Table 3. The consolidated results of 
pre-compression studies of IR and SR layers were 
tabulated in Table 4 [6,7].  
Compression of bilayered tablets  
Bilayered tablets were prepared by direct 
compression method, initially the SR layer was 
compressed and later the upper punch was lifted 
and the blend of IR layer was poured into the die 
and compressed using (Rimek mini press I, India.) 
fitted with a 5 mm standard flat circular punches 
with an average weight of 300 mg and average 
hardness of 6.5 Kg/cm2. 
Post-compression studies of bilayered tablets  
Average weight of tablets  
20 tablets (n=20) were randomly selected from 
each batch and their weight was determined by an 
electronic balance (Sartorius, Germany).  
Thickness  
6 tablets (n=6) were randomly selected from each 
batch and their thickness was measured using a 
vernier calipers (Mitutoyo Corporation, Japan.),  
Hardness  
6 tablets (n=6) were randomly selected from each 
batch and their hardness was measured using a 
Monsanto hardness tester (Secor, India). 
Friability  
The friability of the 20 tablets (n=1) from each 
batch was tested by a friabilator (Roche Friabilator, 
Germany) at a speed of 25 RPM for 4 min. The 
tablets were then de-dusted, re-weighed, and 
percentage weight loss was calculated by the 
equation below,  
% Friability = 
(Initial  Wt .− Wt .after  friability )
Initial  Wt .
 × 100 Eq. 
No. 1 
Assay  
6 tablets from each batch (n=6), were randomly 
selected from each batch IR and SR layers were 
separated by scrapping and crushed in a mortar 
with pestle separately; the quantity of blends 
equivalent to 100mg of drugs (DG/SG) was 
suspended in 100 mL of 0.1N HCl in a volumetric 
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flask and sonicated for 2 min. The dispersion was 
filtered through 0.45μm membrane filter, suitably 
diluted with 0.1N HCl and analyzed by a double 
beam UV-Vis spectrophotometer (Shimadzu-1800, 
Japan) by measuring absorbance at obtained λmax of 
the drug (DG/SG). The consolidated results of post 
compression studies of bilayered tablets are 
tabulated in Table 5. 
In vitro dissolution studies  
In vitro dissolution studies of IR layer  
For to optimize the composition of IR layer, 6 
tablets (n=6) with only compressed IR layer, were 
randomly selected from each batch and undergone 
dissolution in the USP-II (paddle) dissolution 
apparatus (Lab India DS 8000, India), each flask 
was filled with 900 mL of 0.1N HCl; speed of paddle 
was maintained at 50 rpm, the temperature was 
kept constant at 37°C ± 0.5°C. At time points 0, 5, 
10,15,20,25,30, 35, 40 & 45 min, 5 mL of dissolution 
media was withdrawn, filtered through 0.45μm 
membrane filter, suitably diluted and analyzed at 
respective λmax of DG using a double beam UV-Vis 
spectrophotometer (Shimadzu-1800, Japan). Each 
sample withdrawn was replaced with an equal 
amount of fresh 0.1 N HCl, to keep the volume 
constant. In vitro dissolution profiles of DG-IR 
tablets were shown in Fig. 3.  
In vitro dissolution studies of bilayered tablets  
Bilayered tablets containing optimized IR layer and 
varying SR layers in vitro dissolution studies were 
carried out by randomly selecting 6 tablets (n=6) 
from each batch using USP dissolution apparatus 
type II/ paddle (Lab India DS 8000, India) in 900 
mL of 0.1N HCl for first 2 h and in 900 mL of pH 6.8 
Phosphate buffer up to 12 h. Speed of paddle was 
maintained at 50 RPM, the temperature was kept 
constant at 37°C ± 0.5°C. Samples were collected at 
time points 0, 30 (both DG & SG), 60, 120, 180, 240, 
300, 360, 420, 480, 540, 600, 660, 720 min, 5 mL of 
dissolution media was withdrawn, filtered through 
0.45μm membrane filter, suitably diluted and 
analyzed at respective λmax of DG & SG at 30 min and 
for SG at other time points using a double beam UV-
Vis spectrophotometer (Shimadzu-1800, Japan). 
Each sample withdrawn was replaced with an equal 
amount of fresh 0.1N HCl, to keep the volume 
constant. In vitro dissolution profiles of DG/SG 
bilayered tablets were shown in Fig. 4.  
In vitro dissolution kinetics analysis of 
bilayered tablets  
The in vitro drug release data of all batches were 
fitted into Zero order, First order, Higuchi and 
Korsemeyer-Peppas models to ascertain the drug 
release kinetics [8]. The drug release from the 
hydrophilic matrix whether depends on drug’s 
concentration or not was explained by zero and first 
order models. Higuchi model describes whether the 
drug release is predominantly by diffusion or not. 
The Korsemeyer- Peppas model further explains 
the mechanism of diffusion by plotting the first 60% 
of drug release. The respective models were defined 
by the equations below. 
Zero order: Qt=Q0+K0t Eq. No. 2 
First order: Log Q = Log Q0 – K1t /2.303 Eq. No. 3 
Higuchi model: Qt = KH t1/2 Eq. No. 4 
Korsemeyer-peppas model: Mt/Mα = K t n Eq.No. 5 
Where Qt is the amount of drug dissolved at time, t; 
Q0 is the initial amount of drug in the solution at 
time t=0, Q is the amount of drug remaining at time, 
t; Mt/Mα is the fraction of drug released at time, t 
and n is diffusion exponent. K0, K1, KH and K refer to 
the rate constants of respective kinetic models. 
Drug release mechanisms based on n-values, for 
cylindrical shape, as per Korsmeyer-Peppas model, 
were tabulated in Table 6. The consolidated drug 
release kinetic data of SR layer of DG/SG bilayered 
tablets were tabulated in Table 7. 
Accelerated stability studies on optimized 
formulation  
Optimized formulation (BT9 or IR9/SR9), of 20 
tablets in 10 CC HDPE pack up to 3 months were 
carried according to International Conference on 
Harmonization (ICH) guidelines by placing in a 
humidity chamber (NSW-175, Narang Scientific 
work, India) maintained at 45°C ± 2°C and 75% ± 
5% RH [9]. At the end of every month up to 3 
months, the samples were withdrawn and 
evaluated for post compression studies. The 
consolidated results of accelerated stability studies 
were tabulated in Table 8. Comparative in vitro 
dissolution profiles of initial and accelerated 
stability samples were shown in Fig. 5. The 
chemical stability of drug in the 3M-accelerated 
stability sample of optimized formulation (BT9); 
which will influence the in vitro and in vivo 
dissolution characteristics was investigated using 
FT-IR studies. The FT-IR spectra were recorded out 
in the region of 400-4000 cm-1 at spectral 
resolution of 2 cm-1, by the potassium bromide 
pellet method using (Shimadzu-1800, Japan) and 
the comparative FT-IR spectra of optimized BT9-
Initial and 45°C/75RH-3M were shown in Fig. 6. 
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Table 1: Interpretation of Dapagliflozin and Saxagliptin (pure drugs) FT-IR spectra 
 Dapagliflozin Saxagliptin 
Function group 
Standard 
Frequency 
(cm-1) 
 Observed  
Frequency 
(cm-1) 
Function 
group 
Standard 
 frequency 
(cm-1) 
 Observed  
Frequency 
(cm-1) 
C=O Carbonyl 
Stretching 1680-1760  1244  N-H stretching 3000-3700 3433.12 
-OH Stretching 3200-340 3390.12  C-H stretching   2850-2960  2919.18 
C=C Aromatic 
stretching 
1620-1680  
  
1611.92 
  
-OH stretching  3200-3400 3301 
C-N stretching 1600-170 1619.77 
C-O stretching 900-1300 1033.8 
Table 2: Composition of Dapagliflozin (IR) layer and Saxagliptin (SR) layer of bilayered tablets 
Dapagliflozin (IR) tablets 
Ingredients IR1 IR2 IR3 IR4 IR5 IR6 IR7 IR8 IR9 
Dapagliflozin 10 10 10 10 10 10 10 10 10 
SSG 3 6 9 -  -  -  -  -  -  
Lycoat RS 720  -  -  - 3 6 9  -  -  - 
Ludiflash  -  -  -  -  -  - 3 6 9 
PVP K30 20 20 20 20 20 20 20 20 20 
MCC 107 104 101 107 104 101 107 104 101 
Mg. stearate 6 6 6 6 6 6 6 6 6 
Talc 4 4 4 4 4 4 4 4 4 
Total  150 150 150 150 150 150 150 150 150 
 
Dapagliflozin (IR) and Saxagliptin (SR) bilayered tablets 
Ingredients BT1 BT2 BT3 BT4 BT5 BT6 BT7 BT8 BT9 
IR9 150 150 150 150 150 150 150 150 150 
Saxagliptin 5 5 5 5 5 5 5 5 5 
Carbapol 940 30 60 90 - - - - - - 
Karaya gum - - - 30 60 90 - - - 
HPMC K15M - - - - - - 30 60 90 
PVP K30 20 20 20 20 20 20 20 20 20 
 MCC q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
 Talc 4 4 4 4 4 4 4 4 4 
 Mg.stearate 6 6 6 6 6 6 6 6 6 
 Total 300 300 300 300 300 300 300 300 300 
Table 3: Limits for powder flow characteristics (as per USP) 
Flow Character AR (°) CI (%) HR( ) 
Excellent 25–30 ≤ 10 1.00-1.11 
Good 31–35 11-15 1.12-1.18 
Fair 36–40 16-20 1.19-1.25 
Passable 41–45 21-25 1.26-1.34 
Poor 46–55 26-31 1.35-1.45 
Very Poor 56–65 32-37 1.46-1.59 
Very, very Poor >66 > 38 > 1.60 
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Table 4: Results of pre-compression studies of Dapagliflozin (IR) layer and Saxagliptin (SR) layer 
Table 5: Results of post-compression parameters of Dapagliflozin (IR) and Saxagliptin (SR) bilayered 
tablets 
F. Code 
Avg. wt. 
(mg) 
Thickness 
(mm) 
Hardness  
(Kg/cm2) 
Friability  
(%) 
Assay (%) 
DG SG 
BT1 300±1.09 4.42±0.3 6.31±0.40 0.18 98.18±0.90 95.24±0.49 
BT2 299±0.94 4.41±0.5 6.52±0.36 0.14 96.42±0.40 98.41±0.62 
BT3 301±0.59 4.38±0.6 6.11±0.16 0.18 95.90±0.90 98.96±1.06 
BT4 300±1.01 4.43±0.4 6.25±0.22 0.32 98.88±0.10 96.90±0.54 
BT5 300±1.36 4.44±0.4 6.18±0.18 0.12 96.22±1.15 96.19±0.54 
BT6 301±1.58 4.41±0.5 6.14±0.04 0.23 95.44±0.80 98.68±0.16 
BT7 300±0.49 4.42±0.8 6.31±0.01 0.15 95.09±2.15 98.88±0.95 
BT8 300±1.46 4.40±0.9 6.50±0.62 0.13 98.18±0.90 99.58±1.49 
BT9 300±0.95 4.39±0.9 6.42±0.14 0.18 99.14±1.45 96.38±1.21 
Table 6: Diffusion exponent and drug release mechanisms for cylindrical shape (Korsemeyer-Peppas 
model) 
 
 
 
 
 
 
 
Dapagliflozin (IR) layer Saxagliptin (SR) layer 
F. 
Code 
AR BD 
(gm/cm2) 
TD 
(gm/cm2) 
CI 
(%) 
HR F. 
Code 
AR BD 
(gm/cm2) 
TD 
(gm/cm2) 
CI 
(%) 
HR 
IR1 23.54±0.
38 
0.384±0.0
12 
0.424±0.02
6 
10.8
1 
1.1
2 
SR1 33.56±
1.08 
0.58±0.34 0.68±0.30 14.4
8 
1.18 
IR2 23.98±0.
25 
0.388±0.0
24 
0.438±0.01
8 
11.1
1 
1.1
2 
SR2 33.38±
1.01 
0.62±0.25 0.83±0.28 12.5
1 
1.16 
IR3 24.32±0.
24 
0.365±0.0
34 
0.424±0.02
2 
13.1
5 
1.1
5 
SR3 28.63±
0.86 
0.63±0.45 0.88±0.19 15.2
0 
1.19 
IR4 22.42±0.
29 
0.388±0.0
17 
0.438±0.02
9 
13.5
1 
1.1
5 
SR4 28.40±
0.89 
0.68±0.28 0.86±0.54 09.4
8 
1.12 
IR5 23.95±0.
22 
0.389±0.0
12 
0.424±0.02
8 
10.8
1 
1.1
2 
SR5 32.15±
0.94 
0.65±0.51 0.85±0.24 13.1
8 
1.18 
IR6 24.43±0.
23 
0.368±0.0
12 
0.424±0.01
9 
13.1
5 
1.1
5 
SR6 33.53±
0.89 
0.63±0.12 0.86±0.18 14.6
8 
1.19 
IR7 22.34±0.
28 
0.318±0.0
32 
0.418±0.03
7 
11.0
1 
1.1
6 
SR7 31.26±
0.99 
0.62±0.22 0.69±0.53 10.2
8 
1.13 
IR8 23.41±0.
26 
0.353±0.0
26 
0.448±0.01
9 
13.2
1 
1.1
3 
SR8 33.46±
0.98 
0.68±0.46 0.88±0.82 09.2
2 
1.12 
IR9 24.05±0.
12 
0.369±0.0
14 
0.414±0.03
2 
10.4
1 
1.1
1 
SR9 32.60±
0.64 
0.61±0.16 0.68±0.24 13.0
6 
1.18 
Diffusion exponent (n) Drug release Mechanism 
0.45 Fickian diffusion 
0.45 < n <0.89 Anomalous (Non- Fickian) diffusion 
0.89 Case II transport 
n > 0.89 Super Case II transport 
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Table 7: In vitro drug release kinetic analysis of bilayered tablets 
F. Code 
Zero First Higuchi Krosmeyer-Peppas 
r2 r2 r2 r2 n 
BT1 0.986 0.741 0.926 0.934 0.892 
BT2 0.955 0.944 0.931 0.928 0.989 
BT3 0.955 0.618 0.95 0.874 0.834 
BT4 0.988 0.671 0.963 0.987 0.754 
BT5 0.987 0.741 0.874 0.76 0.814 
BT6 0.98 0.681 0.909 0.802 0.763 
BT7 0.991 0.677 0.927 0.779 0.782 
BT8 0.987 0.868 0.914 0.784 0.781 
BT9 0.994 0.868 0.942 0.863 0.792 
Table 8: Results of post-compression parameters of accelerated stability samples of optimized 
Dapagliflozin (IR) and Saxagliptin (SR) bilayered tablets (BT9) 
Time 
duration 
Avg. wt. 
(mg) 
Thickness 
(mm) 
Hardness 
(kg/cm2) 
% Friability 
(%) 
 Assay (%) 
DG SG 
Initial 300±0.95 4.39±0.90 6.42±0.14 0.18 99.14±1.45 96.38±1.21 
1 month 299.8±0.21 4.34±0.12 5.94±0.11 0.24 98.88±0.10 96.23±0.18 
2 month 300.5±0.08 4.32±0.21 5.82±0.20 0.32 98.18±0.90 96.31±0.21 
3 month 300.4±0.70 4.23±0.23 5.78±0.18 0.41 96.42±0.40 96.26±0.12 
 
Fig. 1: FT-IR spectra of a) Dapagliflozin (pure drug); b) Saxagliptin (pure drug)  
 
Fig. 2: Calibration curve of a) Dapagliflozin in 0.1N HCl at 222 nm; b) Saxagliptin in 0.1N HCl at 214 
nm & c) Saxagliptin in pH 6.8 Phosphate buffer at 214 nm 
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Fig. 3: Comparative in vitro dissolution profiles of Dapagliflozin immediate release tablets 
 
Fig. 4: Comparative in vitro dissolution profiles of Dapagliflozin (IR) and Saxagliptin (SR) bilayered 
tablets 
 
Fig. 5: Comparative in vitro dissolution profiles of accelerated stability studies of optimized 
Dapagliflozin (IR) and Saxagliptin (SR) bilayered tablets (BT9) 
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Fig. 6: Comparative FT-IR spectra of optimized formulation a) BT9-Initial b) BT9-40°C/75%RH-3M 
accelerated stability samples 
RESULTS AND DISCUSSION 
Drug-excipient compatibility studies by FT-IR  
An interpretation of FT-IR spectrum of DG and SG 
(pure drugs) reveals that the IR bands of pure drug 
and drug(s) + excipients show no significant shifts 
or reduction in intensity of the FT-IR bands. Hence 
there was no incompatibility problem between the 
drug and excipients used in the study.  
Calibration curve of Dapagliflozin and 
Saxagliptin  
λmax of DG in 0.1N HCl; SG in 0.1N HCl and SG in pH 
6.8 Phosphate buffer are 222 nm, 214 nm and 214 
nm respectively. The standard curves are following 
linearity with a regression coefficient of (r2=0.999). 
They are obeying the Beer’s law in the conc. range 
of 0-30 μg/mL. Lower standard deviation (SD) 
values ensured reproducibility of the method. As 
the excipients used in the study were not 
interfering and good % recovery of drug(s) 
indicates this spectrophotometric method was 
suitable for the estimation of drug(s) in dissolution 
studies and % assay of formulations. 
Pre-compression studies  
The directly compressible blends of IR layer of DG, 
reveals that the angle of repose was found between 
22.34° ± 0.28 to 24.32° ± 0.24, Hausner’s Ratio 
between 1.11 to 1.16 and Carr’s index between 
10.41 to 13.51 %. The directly compressible blends 
of ER layer of SG, reveals that the angle of repose 
was found between 28.40 ° ± 0.89 to 33.56 ° ± 1.08, 
Hausner’s Ratio between 1.12 to 1.19 and Carr’s 
index between 09.22 to 15.20 %. The micromeritic 
studies indicate a good flow and compression 
characteristic of all the IR and SR blends as per USP 
limits as mentioned in Table 3. In these IR & ER 
directly compressible blends MCC is used as diluent, 
which imparts good flow and compressibility to the 
blends [10].  
Post-compression studies of bilayered tablets  
Reveals that the average weight of tablets was 
found to be 299 ± 0.94 to 301 ± 1.58 mg. The 
average thickness of tablets was found to be 4.38 ± 
0.6 to 4.44 ± 0.4 mm. The average hardness of the 
tablets ranges between 6.11 ± 0.16 to 6.52 ± 0.36 
Kg/cm2, indicating satisfactory mechanical strength. 
The % weight loss in the friability test ranges from 
0.28 to 0.48 %, which was NMT 1 % as per 
pharmacopoeia limits indicating a good mechanical 
resistance of tablets. % Assay of DG-IR layer all the 
batches is within 95.09 ± 2.15 to 99.14 ± 1.45 % and 
of SG-SR layer all the batches is within 95.24 ± 0.49 
to 98.88 ± 0.95 % of the labeled content, indicating 
the content uniformity of drug(s) in both IR and SR 
layers. 
In vitro dissolution studies of IR layer  
For the optimization of the composition of IR layer 
In vitro dissolution studies of compressed IR layers 
alone of formulations IR1-IR9 were conducted in 
0.1N HCl up to 45 min. Among all the formulations 
IR9 (6% w/w Ludiflash as superdisintegrant) 
shows the better dissolution efficiency at 30 min 
(DE30). As the concentration of superdisintegrant 
increases, tablet dissolution rate (DR) enhances. 
Among the used superdisintegrant, their order in 
enhancing the DR is SSG < Lycoat RS 720 < 
Ludiflash. Hence IR9 is selected as optimized one 
and in the formulation of all bilayered tablets, its 
composition is taken as IR layer.  
 
IJRAPS, 2018:2(11):296-305 
 Website: http://ijraps.in  304 
In vitro dissolution studies of bilayered tablets  
In vitro dissolution studies of bilayered tablets 
containing optimized IR layer (IR9) and varying 
compositions of SR layers were carried out in 0.1N 
HCl for first 2 h and in pH 6.8 phosphate buffer up 
to 12 h. The cumulative % drug dissolved values of 
DG is similar in all the formulations at 45 min is 
identical due to its similar composition. Related to 
the release profiles SG from SR layer, as the 
concentration of SR polymer increases (Carbapol 
940/Karayagum/HPMCK15M) there is an increased 
viscosity of the gel of matrix and decrease in the 
effective diffusion coefficient of the drug [11]. Other 
factors that may contribute to differences in drug 
release profiles include; differences in water 
penetration rate, water absorption capacity, 
polymer swelling and drug: polymer ratio.[12] 
Among all factors, drug: polymer ratio is important 
factor affecting the rate of drug release from the 
matrix, which has to be optimized. Among all the 
formulations; BT9 (with 60% HPMC K15M as SR 
polymer) extends the release of SG up to 12 h with a 
better zero order release profile.  
In vitro dissolution kinetics analysis  
Among all the formulations; BT9 (with 60% HPMC 
K15M as SR polymer), fitted best to the zero order 
kinetics (as zero order, r2 = 0.994), indicating the 
drug release from the matrix does not depends on 
drug’s concentration. Drug release process is 
predominantly by diffusion (as Higuchi, r2= 0.942; 
i.e. > 0.9); and the mechanism of diffusion is by non-
Fickian diffusion [as Korsemeyer-Peppas, diffusion 
coefficient (n)= 0.792] ( when; 0.45 < n <0.89 then 
non-Fickian diffusion. 
Accelerated stability studies of optimized 
formulation  
As there were no significant differences in post 
compression studies (weight variation, thickness, 
hardness, friability and in vitro dissolution studies) 
of initial and accelerated stability samples of 
optimized formulation BT9 in the final up to 3 
months, it passes the test for stability as per ICH 
guide lines. Comparative FT-IR spectra of optimized 
BT9-Initial and 40°C/75%RH-3M, reveals there is 
no significant change in the functional groups peaks 
of the DG and SG due to interaction with polymers 
and other excipients in the accelerated stability 
studies. 
CONCLUSION  
In the view of above findings, optimization of type 
and concentration of superdisintegrants (SSG/ 
Lycoat RS 720/ Ludiflash) in enhancing the DR of 
DG from the IR layer of BT was understood. 
Optimization of type and conc. of SR polymers 
(Carbapol 940/ Karaya gum/ HPMC K15M) in 
extending the release of SG from the SR layer of BT 
was better understood. It was further concluded 
that the optimization of the ratio of Drug (SG): SR 
polymer (HPMC K15M), had significant effect on 
extending the release profiles of SG up to 12 h with 
zero order release profile. Among the three SR 
polymers, (SG: HPMC K15M in the ratio 1:18) 
respectively forms a better matrix for the extending 
the release of SG up to 12 h from the SR layer of BT. 
The optimized formulation; BT9 [IR9 (6 % w/w 
Ludiflash as superdisintegrant and SR9 (with 60% 
HPMC K15M as SR polymer)] releases 100% of DG 
from the IR layer and extends the release of SG up 
to 12 h with a better zero order release profile 
(r2=0.994). A combination of these two classes 
[SGLT-2 inhibitors (DG) and DPP-4 inhibitors (SG)] 
of glucose-lowering agents and formulating them as 
a bilayered tablet of DG as IR layer and SG as SR 
layer is more effective in the treatment and 
maintenance of type 2 diabetes mellitus. 
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